Vanda Pharmaceuticals (VNDA) Cash from Operations (2010 - 2026)
Vanda Pharmaceuticals (VNDA) reported Cash from Operations of 50218000.0 for Q1 2026, down 51.5% on a YoY basis from 103544168.08 in Q1 2025, and down 70.71% sequentially from 29417000.0 in Q4 2025.
Vanda Pharmaceuticals (VNDA) Cash from Operations (2010 - 2026) Analysis & Trends
Vanda Pharmaceuticals (VNDA) has 17 years of Cash from Operations data on file, last reported at 50218000.0 in Q1 2026.
- For the quarter ending Q1 2026, Cash from Operations fell 51.5% year-over-year to 50218000.0; the trailing twelve-month figure through Mar 2026 stood at 126513000.0 (down 124.02% YoY), and the FY2025 full-year result was 109442000.0, down 594.56% from the prior year.
- Cash from Operations retreated to 50218000.0 in Q1 2026, from 29417000.0 in the prior quarter.
- In the past five years, Cash from Operations ranged from a high of 31803000.0 in Q1 2023 to a low of 50218000.0 in Q1 2026.
- A 5-year average of 7684235.29 and a median of 3732000.0 in 2023 frame the typical range for Cash from Operations.
- Across the five-year window, Cash from Operations soared 686.04% in 2023 and sank 1518.99% in 2025, its largest moves.
- Tracing VNDA's Cash from Operations over 5 years: stood at 9416000.0 in 2022, then tumbled by 139.63% to 3732000.0 in 2023, then jumped by 51.31% to 1817000.0 in 2024, then slumped by 1518.99% to 29417000.0 in 2025, then sank by 70.71% to 50218000.0 in 2026.
- Business Quant data shows VNDA's Cash from Operations at 50218000.0 in Q1 2026, 29417000.0 in Q4 2025, and 31626000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -19.59 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 201.34 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.53 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.43 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 1.08 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -354.17 Mn |
| 10 | Vanda Pharmaceuticals | 318.71 Mn | 116.40 Mn | 48.56 Mn | -50.22 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -50.22 Mn |
| Mar 31, 2026 | -50.22 Mn |
| Dec 31, 2025 | -29.42 Mn |
| Dec 31, 2025 | -29.42 Mn |
| Sep 30, 2025 | -31.63 Mn |
| Sep 30, 2025 | -31.63 Mn |
| Jun 30, 2025 | -15.25 Mn |
| Jun 30, 2025 | -15.25 Mn |
| Mar 31, 2025 | -33.15 Mn |
| Mar 31, 2025 | -33.15 Mn |
| Dec 31, 2024 | -1.82 Mn |
| Dec 31, 2024 | -1.82 Mn |
| Sep 30, 2024 | -14.58 Mn |
| Sep 30, 2024 | -14.58 Mn |
| Jun 30, 2024 | -6.93 Mn |
| Jun 30, 2024 | -6.93 Mn |
| Mar 31, 2024 | 7.57 Mn |
| Mar 31, 2024 | 7.57 Mn |
| Dec 31, 2023 | -3.73 Mn |
| Dec 31, 2023 | -3.73 Mn |